Shivaani Kummar
OHSU Knight Cancer Institute · Oregon Health and Science University · ECOG-ACRIN Cancer Research Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Shivaani Kummar as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:06 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT06320405 · Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid TumorsOHSU Knight Cancer Institute · recruiting · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm · principal investigator
- Ph1NCT04601402 · GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 TherapyGenome & Company · completed · Solid Tumor, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck · principal investigator
- Ph2NCT04439227 · Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)National Cancer Institute (NCI) · active not recruiting · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm · principal investigator
- Ph2NCT04260256 · A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid TumorsCellSight Technologies, Inc. · terminated · Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit · principal investigator
- Ph1/Ph2NCT03345485 · Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.Mundipharma Research Limited · completed · Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer · principal investigator
- Ph1NCT01445522 · ABT-888 Plus Metronomic Cyclophosphamide to Treat CancerNational Cancer Institute (NCI) · completed · Neoplasms, Lymphoma · principal investigator
- Ph2NCT01333475 · MK-2206 and AZD6244 in Patients With Advanced Colorectal CarcinomaNational Cancer Institute (NCI) · completed · Colorectal Neoplasms · principal investigator
- Ph1NCT01251926 · EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid TumorsNational Cancer Institute (NCI) · completed · Neoplasms · principal investigator
- Ph1NCT01240577 · An Early Phase I Study of IPdR Absorption, Metabolism, and Safety in Patients With Advanced Solid Tumors and LymphomasNational Cancer Institute (NCI) · completed · Neoplasms, Lymphoma · principal investigator
- Ph1NCT01120288 · A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver MetastasesNational Cancer Institute (NCI) · completed · Neoplasms, Liver Metastases · principal investigator
- Ph2NCT00923481 · A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...National Cancer Institute (NCI) · completed · Head and Neck Neoplasms, Pheochromocytoma, Colorectal Neoplasms · principal investigator
- Ph1NCT00734890 · Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or LymphomaNational Institutes of Health Clinical Center (CC) · completed · Lung Cancer, Lymphoma, Lymphoproliferative Disorder · principal investigator
- Ph1NCT00674024 · Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver FunctionNational Cancer Institute (NCI) · completed · Neoplasms, Lymphoma · principal investigator
- Ph1NCT00589381 · Fenretinide Lym-X-Sorb™ in Treating Patients With Recurrent or Resistant Solid Tumors or LymphomaNational Institutes of Health Clinical Center (CC) · completed · Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific · study chair
- Ph1NCT00450502 · Safety of Batracylin in Patients With Solid Tumors and LymphomasNational Cancer Institute (NCI) · completed · Neoplasms · principal investigator
- Ph1NCT00387608 · ABT-888 in Patients With Refractory Solid Tumors or Hematologic CancerNational Institutes of Health Clinical Center (CC) · completed · Leukemia, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific · principal investigator
- Ph2NCT00326495 · BAY 43-9006 Plus Cetuximab to Treat Colorectal CancerNational Cancer Institute (NCI) · completed · Metastatic Colorectal Cancer · principal investigator
- Ph1NCT00088868 · 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or LymphomaNational Institutes of Health Clinical Center (CC) · completed · Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific · principal investigator
- Ph1NCT00020579 · MS-275 in Treating Patients With Advanced Solid Tumors or LymphomaNational Institutes of Health Clinical Center (CC) · completed · Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:06 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Experimental Therapeutics in Cancer Training ProgramT32CA285265 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · fiscal years 2025 to 2026 · $268,200 awarded in 2026Same name and institution; not confirmed by an ID
- OHSU Knight Cancer InstituteP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · fiscal years 2022 to 2026 · $2,891,535 awarded in 2026Same name and institution; not confirmed by an ID
- [18F]-AraG -PET imaging to evaluate immunological response to checkpoint inhibitor therapy (CKI) in patients with advanced solid tumorsR01CA240638 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · fiscal years 2020 to 2025 · $124,109 awarded in 2025Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026Named on NCT04439227
- ECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · fiscal years 2015 to 2026Named on NCT04439227
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:06 UTC. The ranking covers the 200 most relevant of 72 PubMed records, and a shared surname and initials can bring in a namesake. All 72 on PubMed
- 2,232 citationsRCR 80.0
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.Lancet Oncol · 2020856 citationsRCR 36.6
- Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.Cancer Discov · 2020298 citationsRCR 11.1
- Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.J Clin Oncol · 2015287 citationsRCR 7.6
- SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study.Cancer Discov · 2018277 citationsRCR 8.1
- Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.J Clin Oncol · 2009265 citationsRCR 5.3
- Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors.N Engl J Med · 2023229 citationsRCR 21.4
- Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.Cancer Res · 2011213 citationsRCR 4.7
- Cediranib for metastatic alveolar soft part sarcoma.J Clin Oncol · 2013168 citationsRCR 4.7
- A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas.Clin Cancer Res · 2012162 citationsRCR 4.0